EUROFINS SCIENT (OTCMKTS:ERFSF) Shares Gap Up - Here's What Happened

Key Points

• EUROFINS SCIENT shares opened at $79.78, after previously closing at $76.99, indicating a positive market reaction.
• Analysts from HSBC and Citigroup have recently rated the stock as "hold" or "neutral," leading to an average rating of "Hold" across five analysts.
• The company provides a variety of analytical testing and laboratory services globally, focusing on evaluating the safety and composition of various products.

EUROFINS SCIENT (OTCMKTS:ERFSF - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $76.99, but opened at $79.78. EUROFINS SCIENT shares last traded at $79.78, with a volume of 67 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HSBC lowered EUROFINS SCIENT to a "hold" rating in a report on Friday, April 25th. Citigroup reiterated a "neutral" rating on shares of EUROFINS SCIENT in a research report on Friday, July 25th. Finally, Hsbc Global Res lowered EUROFINS SCIENT from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Five analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold".

EUROFINS SCIENT Price Performance

The firm has a 50 day moving average of $72.83 and a 200-day moving average of $62.51. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.26 and a quick ratio of 1.19.

EUROFINS SCIENT Company Profile

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.